Back to top

gene-therapy: Archive

Zacks Equity Research

bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well

bluebird (BLUE) beats sales estimates in the first quarter on increased Zynteglo product revenues. The company is on track with the ongoing launch of its gene therapies.

VRTXNegative Net Change HTGCPositive Net Change BLUENegative Net Change CRSPNegative Net Change

Zacks Equity Research

CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss

CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.

VRTXNegative Net Change UTHRNegative Net Change LGNDNegative Net Change CRSPNegative Net Change